NICE to recommend Remicade and Humira for Crohn's disease
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, is set to recommend Abbott's Humira (adalimumab) and Merck & Co (MSD/Schering-Plough)'s Remicade (infliximab) for some NHS patients with Crohn's disease.